LinkedIn Profile

Access pan-Canadian Oncology Drug Review historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:pan-canadianoncologydrugreview-2 1575892 May 30th, 2019 12:00AM pan-Canadian Oncology Drug Review 313 7.00 Open Government Administration May 30th, 2019 07:47PM May 30th, 2019 07:47PM The pan-Canadian Oncology Drug Review (pCODR) was established by the provincial and territorial Ministries of Health to assess the clinical evidence and cost effectiveness of new cancer drugs and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions. It evolved from the interim Joint Oncology Drug Review (JODR), which demonstrated the significant value that a national collaborative platform provides to cancer care decision making. The pCODR process brings consistency and clarity to the cancer drug review process, ensuring individual provinces and territories can make drug funding decisions informed by evidence. Along with the provincial and territorial Ministries of Health, with the exception of Quebec, other partners in the pCODR process are provincial cancer agencies, the Canadian Partnership Against Cancer and the Canadian Agency for Drugs and Technology in Health. Open pan-Canadian Oncology Drug Review Pharmaceuticals & Biotechnology
private:pan-canadianoncologydrugreview-2 1575892 Mar 9th, 2018 12:00AM pan-Canadian Oncology Drug Review 301 8.00 Open Government Administration Mar 9th, 2018 10:37AM Mar 9th, 2018 10:37AM Open pan-Canadian Oncology Drug Review Pharmaceuticals & Biotechnology
private:pan-canadianoncologydrugreview-2 1575892 Feb 17th, 2018 12:00AM pan-Canadian Oncology Drug Review 292 9.00 Open Government Administration Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM The pan-Canadian Oncology Drug Review (pCODR) was established by the provincial and territorial Ministries of Health to assess the clinical evidence and cost effectiveness of new cancer drugs and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions. It evolved from the interim Joint Oncology Drug Review (JODR), which demonstrated the significant value that a national collaborative platform provides to cancer care decision making. The pCODR process brings consistency and clarity to the cancer drug review process, ensuring individual provinces and territories can make drug funding decisions informed by evidence. Along with the provincial and territorial Ministries of Health, with the exception of Quebec, other partners in the pCODR process are provincial cancer agencies, the Canadian Partnership Against Cancer and the Canadian Agency for Drugs and Technology in Health. pan-Canadian Oncology Drug Review Pharmaceuticals & Biotechnology
private:pan-canadianoncologydrugreview-2 1575892 Feb 16th, 2018 12:00AM pan-Canadian Oncology Drug Review 292 9.00 Open Government Administration Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM The pan-Canadian Oncology Drug Review (pCODR) was established by the provincial and territorial Ministries of Health to assess the clinical evidence and cost effectiveness of new cancer drugs and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions. It evolved from the interim Joint Oncology Drug Review (JODR), which demonstrated the significant value that a national collaborative platform provides to cancer care decision making. The pCODR process brings consistency and clarity to the cancer drug review process, ensuring individual provinces and territories can make drug funding decisions informed by evidence. Along with the provincial and territorial Ministries of Health, with the exception of Quebec, other partners in the pCODR process are provincial cancer agencies, the Canadian Partnership Against Cancer and the Canadian Agency for Drugs and Technology in Health. pan-Canadian Oncology Drug Review Pharmaceuticals & Biotechnology
private:pan-canadianoncologydrugreview-2 1575892 Feb 15th, 2018 12:00AM pan-Canadian Oncology Drug Review 292 9.00 Open Government Administration Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM The pan-Canadian Oncology Drug Review (pCODR) was established by the provincial and territorial Ministries of Health to assess the clinical evidence and cost effectiveness of new cancer drugs and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions. It evolved from the interim Joint Oncology Drug Review (JODR), which demonstrated the significant value that a national collaborative platform provides to cancer care decision making. The pCODR process brings consistency and clarity to the cancer drug review process, ensuring individual provinces and territories can make drug funding decisions informed by evidence. Along with the provincial and territorial Ministries of Health, with the exception of Quebec, other partners in the pCODR process are provincial cancer agencies, the Canadian Partnership Against Cancer and the Canadian Agency for Drugs and Technology in Health. pan-Canadian Oncology Drug Review Pharmaceuticals & Biotechnology
private:pan-canadianoncologydrugreview-2 1575892 Feb 14th, 2018 12:00AM pan-Canadian Oncology Drug Review 292 9.00 Open Government Administration Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM The pan-Canadian Oncology Drug Review (pCODR) was established by the provincial and territorial Ministries of Health to assess the clinical evidence and cost effectiveness of new cancer drugs and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions. It evolved from the interim Joint Oncology Drug Review (JODR), which demonstrated the significant value that a national collaborative platform provides to cancer care decision making. The pCODR process brings consistency and clarity to the cancer drug review process, ensuring individual provinces and territories can make drug funding decisions informed by evidence. Along with the provincial and territorial Ministries of Health, with the exception of Quebec, other partners in the pCODR process are provincial cancer agencies, the Canadian Partnership Against Cancer and the Canadian Agency for Drugs and Technology in Health. pan-Canadian Oncology Drug Review Pharmaceuticals & Biotechnology
private:pan-canadianoncologydrugreview-2 1575892 Feb 13th, 2018 12:00AM pan-Canadian Oncology Drug Review 292 9.00 Open Government Administration Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM The pan-Canadian Oncology Drug Review (pCODR) was established by the provincial and territorial Ministries of Health to assess the clinical evidence and cost effectiveness of new cancer drugs and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions. It evolved from the interim Joint Oncology Drug Review (JODR), which demonstrated the significant value that a national collaborative platform provides to cancer care decision making. The pCODR process brings consistency and clarity to the cancer drug review process, ensuring individual provinces and territories can make drug funding decisions informed by evidence. Along with the provincial and territorial Ministries of Health, with the exception of Quebec, other partners in the pCODR process are provincial cancer agencies, the Canadian Partnership Against Cancer and the Canadian Agency for Drugs and Technology in Health. pan-Canadian Oncology Drug Review Pharmaceuticals & Biotechnology
private:pan-canadianoncologydrugreview-2 1575892 Feb 12th, 2018 12:00AM pan-Canadian Oncology Drug Review 292 9.00 Open Government Administration Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM The pan-Canadian Oncology Drug Review (pCODR) was established by the provincial and territorial Ministries of Health to assess the clinical evidence and cost effectiveness of new cancer drugs and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions. It evolved from the interim Joint Oncology Drug Review (JODR), which demonstrated the significant value that a national collaborative platform provides to cancer care decision making. The pCODR process brings consistency and clarity to the cancer drug review process, ensuring individual provinces and territories can make drug funding decisions informed by evidence. Along with the provincial and territorial Ministries of Health, with the exception of Quebec, other partners in the pCODR process are provincial cancer agencies, the Canadian Partnership Against Cancer and the Canadian Agency for Drugs and Technology in Health. pan-Canadian Oncology Drug Review Pharmaceuticals & Biotechnology
private:pan-canadianoncologydrugreview-2 1575892 Feb 11th, 2018 12:00AM pan-Canadian Oncology Drug Review 292 9.00 Open Government Administration Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM The pan-Canadian Oncology Drug Review (pCODR) was established by the provincial and territorial Ministries of Health to assess the clinical evidence and cost effectiveness of new cancer drugs and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions. It evolved from the interim Joint Oncology Drug Review (JODR), which demonstrated the significant value that a national collaborative platform provides to cancer care decision making. The pCODR process brings consistency and clarity to the cancer drug review process, ensuring individual provinces and territories can make drug funding decisions informed by evidence. Along with the provincial and territorial Ministries of Health, with the exception of Quebec, other partners in the pCODR process are provincial cancer agencies, the Canadian Partnership Against Cancer and the Canadian Agency for Drugs and Technology in Health. pan-Canadian Oncology Drug Review Pharmaceuticals & Biotechnology
private:pan-canadianoncologydrugreview-2 1575892 Feb 10th, 2018 12:00AM pan-Canadian Oncology Drug Review 292 9.00 Open Government Administration Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM The pan-Canadian Oncology Drug Review (pCODR) was established by the provincial and territorial Ministries of Health to assess the clinical evidence and cost effectiveness of new cancer drugs and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions. It evolved from the interim Joint Oncology Drug Review (JODR), which demonstrated the significant value that a national collaborative platform provides to cancer care decision making. The pCODR process brings consistency and clarity to the cancer drug review process, ensuring individual provinces and territories can make drug funding decisions informed by evidence. Along with the provincial and territorial Ministries of Health, with the exception of Quebec, other partners in the pCODR process are provincial cancer agencies, the Canadian Partnership Against Cancer and the Canadian Agency for Drugs and Technology in Health. pan-Canadian Oncology Drug Review Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.